Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 858946, 13 pages
Research Article

STAT6 siRNA Matrix-Loaded Gelatin Nanocarriers: Formulation, Characterization, and Ex Vivo Proof of Concept Using Adenocarcinoma Cells

1Department of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawai’i at Hilo, 200 W. Kawili Street, Hilo, HI 96720, USA
2Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawai’i, 651 Ilalo Street, Honolulu, HI 96813, USA

Received 1 May 2013; Accepted 13 August 2013

Academic Editor: Kamla Pathak

Copyright © 2013 Susanne R. Youngren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The clinical utility of siRNA therapy has been hampered due to poor cell penetration, nonspecific effects, rapid degradation, and short half-life. We herewith proposed the formulation development of STAT6 siRNA (S6S) nanotherapeutic agent by encapsulating them within gelatin nanocarriers (GNC). The prepared nanoformulation was characterized for size, charge, loading efficiency, release kinetics, stability, cytotoxicity, and gene silencing assay. The stability of S6S-GNC was also assessed under conditions of varying pH, serum level, and using electrophoretic assays. In vitro cytotoxicity performance was evaluated in human adenocarcinoma A549 cells following MTT assay. The developed formulation resulted in an average particle size, surface charge, and encapsulation efficiency as  nm,  mV, and , respectively. S6S-GNC showed an insignificant ( ) change in the size and charge in the presence of buffer solutions (pH 6.4 to 8.4) and FBS (10% v/v). A549 cells were treated with native S6S, S6S-lipofectamine, placebo-GNC, and S6S-GNC using untreated cells as a control. It was observed that cell viability was decreased significantly with S6S-GNC by ( ) compared to native S6S ( %) and S6S-lipofectamine complex ( . This investigation infers that gelatin polymer-based nanocarriers are a robust, stable, and biocompatible strategy for the delivery of siRNA.